The maximum study duration per patient will be approximately 20 weeks that will consist of a 4-week screening and training period including a 1-2 week CGM performance (allow for re-training), a 14-week open-label, comparative treatment period allowing for dose titration in both basal and meal-time insulin, a 1-2 week blinded CGM collection with fixed dose of Toujeo and Lantus, and a 2 day post treatment follow-up period.